While semaglutide is a GLP-1 agonist, tirzepatide is known as a dual glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist (GIP/GLP-1 agonist)
This dual action on both glucose metabolism and appetite has made GLP-1 a therapeutic target for type 2 diabetes and obesity management
3,4 Human DPP4 comprises 766 amino acids, with a 738-amino-acid extracellular portion, a 6-amino-acid cytoplasmic tail, and a 22-amino-acid transmembrane hydrophobic segment
If you or a loved one experienced severe side effects from GLP-1 drugs, understanding the eligibility process and your legal options can help you decide the best path forward
However, Qsymia is generally more cost-effective
Published February 25, 2017